What is NDC 70710-1396?

70710-1396 is the product NDC for Eltrombopag, Eltrombopag olamine 25 mg/1 tablet, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Eltrombopag?

37 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Eltrombopag NDC 70710-1396 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1396Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1396Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1396-3	70710139603	30 TABLET in 1 BOTTLE (70710-1396-3)Marketed from Jan 14, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Eltrombopag
Generic name (nonproprietary): eltrombopag
Active ingredients: Eltrombopag olamine — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Zydus Pharmaceuticals USA Inc.NDC labeler code 70710
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216281
Marketing start: Jan 14, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Breast Cancer Resistance Protein Inhibitors (Mechanism)Increased Megakaryocyte Maturation (Physiologic effect)Increased Platelet Production (Physiologic effect)Organic Anion Transporting Polypeptide 1B1 Inhibitors (Mechanism)Thrombopoietin Receptor Agonists (Mechanism)UGT1A1 Inhibitors (Mechanism)UGT1A3 Inhibitors (Mechanism)UGT1A4 Inhibitors (Mechanism)UGT1A6 Inhibitors (Mechanism)UGT1A9 Inhibitors (Mechanism)UGT2B15 Inhibitors (Mechanism)UGT2B7 Inhibitors (Mechanism)
Identifiers: Product ID 70710-1396_8f8b3109-d174-4138-b14f-f956a4578ca9SPL ID 8f8b3109-d174-4138-b14f-f956a4578ca9SPL set ID 1cfdd1fa-d687-41f9-a160-9491f0beac1eRxCUI 825421, 825427, 884617, 1245001UNII 4U07F515LGUPC 0370710139636, 0370710139735
Pharmacologic class: Thrombopoietin Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710139603 followed by a unit qualifier and the quantity

Package 70710-1396-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 21, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Eltrombopag is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Eltrombopag should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents th…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70710-1396

What is NDC 70710-1396?: 70710-1396 is the product NDC for Eltrombopag, Eltrombopag olamine 25 mg/1 tablet, listed with the FDA by Zydus Pharmaceuticals USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Eltrombopag.
What is the active ingredient?: Eltrombopag olamine.
Who is the labeler?: Zydus Pharmaceuticals USA Inc., NDC labeler code 70710. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Eltrombopag?: 37 other product NDCs are listed under this name. See all Eltrombopag NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Eltrombopag NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Eltrombopag	Eltrombopag olamine 12.5 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-4015	00480-4015-56
Eltrombopag	Eltrombopag olamine 75 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-4031	00480-4031-56
Eltrombopag	Eltrombopag olamine 25 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-4210	00480-4210-56
Eltrombopag	Eltrombopag olamine 50 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-2600	00480-2600-56
Eltrombopageltrombopag olamine	Eltrombopag olamine 50 mg/1	Tablet, Film coatedOral	Biocon Pharma Inc.	70377-185	70377-0185-1170377-0185-1270377-0185-13
Eltrombopag	Eltrombopag olamine 12.5 mg/1	Tablet, Film coatedOral	Biocon Pharma Inc.	70377-183	70377-0183-11
Eltrombopageltrombopag olamine	Eltrombopag olamine 25 mg/1	Tablet, Film coatedOral	Biocon Pharma Inc.	70377-184	70377-0184-1170377-0184-12
Eltrombopageltrombopag olamine	Eltrombopag olamine 75 mg/1	Tablet, Film coatedOral	Biocon Pharma Inc.	70377-186	70377-0186-1170377-0186-12
Eltrombopageltrombopag olamine	Eltrombopag olamine 12.5 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-0962	00054-0962-13
Eltrombopageltrombopag olamine	Eltrombopag olamine 75 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-0965	00054-0965-13

All 38 Eltrombopag NDCs

Other NDCs under ANDA 216281

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216281
Product	Strength	Form · route	Labeler	Product NDC
Eltrombopag	Eltrombopag olamine 12.5 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1925
Eltrombopag	Eltrombopag olamine 75 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1928
Eltrombopag	Eltrombopag olamine 25 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1926
Eltrombopag	Eltrombopag olamine 50 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1927
Eltrombopag	Eltrombopag olamine 12.5 mg/1	TabletOral	Zydus Pharmaceuticals USA Inc.	70710-1395
Eltrombopag	Eltrombopag olamine 50 mg/1	TabletOral	Zydus Pharmaceuticals USA Inc.	70710-1397
Eltrombopag	Eltrombopag olamine 75 mg/1	TabletOral	Zydus Pharmaceuticals USA Inc.	70710-1398